相关临床试验
55
13 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1949
已完成
25
45.5%
尚未招募
13
23.6%
招募中
14
25.4%
Unknown
3
5.5%
暂无批准数据
- Researchers at the University of Illinois Urbana-Champaign and Mie University found that the bacterial peptide corisin directly drives pulmonary fibrosis by disrupting the cell's mitochondrial quality-control system. - Corisin-producing bacteria were detected in lung fluid from pulmonary fibrosis patients, and neutralizing corisin with an antibody eliminated the fluid's lethal effects on healthy cells. - Mice engineered to continuously produce corisin in their lungs spontaneously developed pulmonary fibrosis, while treatment with a corisin-binding antibody reduced fibrosis, disease severity, and improved survival. - The findings provide proof of concept that neutralizing corisin could represent an entirely new therapeutic strategy for pulmonary fibrosis and potentially fibrotic diseases affecting other organs.
- Health and Global Policy Institute (HGPI) hosted two non-partisan Diet member briefings addressing hearing loss policy challenges and regional cancer care equalization in Japan. - Professor Koichiro Wasano of Tokai University presented the current status and policy challenges of addressing hearing loss in Japan to legislators. - Professors Kazuhiro Tateda and Masaki Tanabe discussed the tension between equalization and centralization in regional cancer care delivery. - The briefings aimed to deepen legislative understanding using concrete data on high public-interest themes including cancer, preventive medicine, and pediatrics.
